Discover the latest milestone in child healthcare as Indian Immunologicals Ltd introduces Mabella, a groundbreaking Measles and Rubella vaccine for children. Developed in collaboration with Polyvac Institute, Vietnam, this live attenuated MR vaccine aims to significantly reduce the global toll of 1,00,000 children claimed by Measles and Rubella.
In a significant stride towards child healthcare, Indian Immunologicals Ltd (IIL) has unveiled Mabella, a new Measles and Rubella (MR) vaccine designed exclusively for children. The live attenuated MR vaccine, developed in partnership with Polyvac Institute, Vietnam, has undergone rigorous human clinical trials, demonstrating both safety and efficacy.
Understanding Measles and Rubella:
Measles and Rubella, highly contagious viral diseases, pose significant threats to children’s health globally. Measles manifests with symptoms like fever, cough, and a characteristic rash, while Rubella, also known as German measles, often presents with a mild rash and fever. These diseases can lead to severe complications, affecting vision, hearing, and even causing birth defects if contracted during pregnancy.
Currently, the global healthcare system addresses Measles and Rubella through various treatment options, including supportive care to alleviate symptoms. However, prevention remains the key, and vaccination has proven to be the most effective strategy.
Vaccination: A Shield Against Measles and Rubella:
Vaccines play a pivotal role in preventing and controlling infectious diseases. They stimulate the immune system to recognize and fight specific viruses or bacteria, providing immunity without causing the disease itself. The introduction of vaccines has been a game-changer in reducing the incidence and severity of Measles and Rubella.
Indian Immunologicals Ltd, known for its commitment to public health, has emerged as a key player in vaccine development. The Mabella vaccine represents a significant achievement in the company’s dedication to eliminating and eradicating diseases. K Anand Kumar, Managing Director of IIL, highlighted the vaccine’s safety and effectiveness, reinforcing the company’s focus on saving lives.
Global Impacts of IIL’s Vaccine:
Measles and Rubella claim the lives of approximately 1,00,000 children globally, making IIL’s efforts even more critical. Kumar emphasized the company’s commitment to disease elimination over the sheer volume of vaccine doses sold. IIL’s Corporate Social Responsibility (CSR) activities extend to making Thiruvanathapuram district rabies-free, showcasing a holistic approach to public health.
Contributions of Human Biologicals Institute (HBI):
A division of IIL, Human Biologicals Institute (HBI), established in 1998, has played a pivotal role in contributing to a self-reliant India. Notably, HBI developed India’s first safe Vero-cell rabies vaccine, Abhayrab, in 1998, leading to the phasing out of the painful nerve tissue vaccine. Abhayrab is now the largest-selling Anti-Rabies vaccine globally.
IIL’s Role in UIP and Global Vaccine Exports:
IIL has solidified its position as one of the largest suppliers of human vaccines to the Universal Immunization Programme (UIP), under the Ministry of Health and Family Welfare. The company’s global reach extends to exporting vaccines to more than 50 countries, showcasing its commitment to global health.
Towards Atmanirbhar Bharat:
HBI’s establishment in 1998 aligns with the vision of ‘Atmanirbhar Bharat’ or a self-reliant India. The institute has been at the forefront of developing indigenous vaccines, including childhood vaccines like DPT, Pentavalent Vaccine, TT, and Hepatitis-B, contributing significantly to the nation’s healthcare infrastructure.
A Healthier Future for Children:
In launching Mabella, Indian Immunologicals Ltd marks a crucial step forward in safeguarding the health of children against the threats posed by Measles and Rubella. The live attenuated MR vaccine, a result of collaboration with Polyvac Institute, Vietnam, not only represents a breakthrough in vaccine technology but also underscores IIL’s commitment to creating a healthier and disease-free future for the global community. As we witness this milestone, it becomes evident that the pursuit of innovative solutions and strategic partnerships is vital in tackling global health challenges.